GPP
Great Point Partners Portfolio holdings
AUM
$154M
This Quarter Return
+39.59%
1 Year Return
-2.36%
3 Year Return
+169.3%
5 Year Return
+292.82%
10 Year Return
+3,519.88%
AUM
$587M
AUM Growth
+$587M
(+10%)
Cap. Flow
-$98.3M
Cap. Flow
% of AUM
-16.76%
Top 10 Holdings %
Top 10 Hldgs %
58.11%
Holding
50
New
10
Increased
7
Reduced
12
Closed
15
Top Buys
| 1 |
Neurogene
NGNE
|
$19.3M |
| 2 |
ABVX
Abivax
ABVX
|
$16.6M |
| 3 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$11.9M |
| 4 |
Arvinas
ARVN
|
$9.63M |
| 5 |
VistaGen Therapeutics
VTGN
|
$9.55M |
Top Sells
| 1 |
PNT
POINT Biopharma Global Inc. Common Stock
PNT
|
$19.4M |
| 2 |
Arcellx
ACLX
|
$13.3M |
| 3 |
Aclaris Therapeutics
ACRS
|
$11.6M |
| 4 |
PTC Therapeutics
PTCT
|
$11.2M |
| 5 |
Replimune Group
REPL
|
$10.9M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALPN
1
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $70.6M | 12.03% | 3,703,433 +624,800 | +20% | +$11.9M |
|
2
Cytokinetics
CYTK
$4.23B
| $41.7M | 7.11% | 500,000 -100,000 | -17% | -$8.35M |
|
3
UroGen Pharma
URGN
$900M
| $39.3M | 6.7% | 2,620,545 | – | – |
|
4
Pliant Therapeutics
PLRX
$101M
| $33M | 5.63% | 1,823,184 +68,000 | +4% | +$1.23M |
|
5
Ultragenyx Pharmaceutical
RARE
$2.89B
| $31M | 5.28% | 648,000 -79,426 | -11% | -$3.8M |
|
6
Xenon Pharmaceuticals
XENE
$2.98B
| $27.6M | 4.71% | 600,000 +99,999 | +20% | +$4.61M |
|
7
RAPT Therapeutics
RAPT
$188M
| $27.3M | 4.66% | 1,099,753 -358,317 | -25% | -$8.9M |
|
8
Alkermes
ALKS
$4.78B
| $24.3M | 4.14% | 875,044 | – | – |
|
|
JBIO
9
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $23.5M | 4% | 1,037,690 -53,543 | -5% | -$1.21M |
|
10
Vaxcyte
PCVX
$4B
| $22.6M | 3.85% | 360,000 -171,211 | -32% | -$10.8M |
|
11
Evolus
EOLS
$494M
| $21.1M | 3.59% | 2,000,000 -186,934 | -9% | -$1.97M |
|
12
AnaptysBio
ANAB
$569M
| $20.9M | 3.57% | 976,981 +82,648 | +9% | +$1.77M |
|
13
Immunocore
IMCR
$1.62B
| $20M | 3.41% | 293,000 +2,083 | +0.7% | +$142K |
|
|
14
Neurogene
NGNE
$264M
| $19.3M | 3.28% | +994,229 | New | +$19.3M |
|
15
Amicus Therapeutics
FOLD
$2.34B
| $18.2M | 3.1% | 1,280,500 +423,500 | +49% | +$6.01M |
|
16
Tourmaline Bio
TRML
$601M
| $17.6M | 3% | 672,885 -327,115 | -33% | -$8.56M |
|
|
ABVX
17
Abivax
ABVX
$6.12B
| $16.6M | 2.83% | +1,550,000 | New | +$16.6M |
|
18
Zura Bio
ZURA
$133M
| $15.4M | 2.62% | 3,295,000 | – | – |
|
|
OPTN
19
DELISTED
OptiNose
OPTN
| $11.4M | 1.94% | 8,839,939 | – | – |
|
20
Apogee Therapeutics
APGE
$2.17B
| $11.2M | 1.9% | 400,000 | – | – |
|
|
21
Arvinas
ARVN
$568M
| $9.63M | 1.64% | +234,082 | New | +$9.63M |
|
|
KRTX
22
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $9.57M | 1.63% | 30,250 -30,250 | -50% | -$9.57M |
|
|
23
VistaGen Therapeutics
VTGN
$102M
| $9.55M | 1.63% | +1,858,735 | New | +$9.55M |
|
24
Terns Pharmaceuticals
TERN
$609M
| $8.5M | 1.45% | 1,309,975 +664,076 | +103% | +$4.31M |
|
|
ITCI
25
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $7.92M | 1.35% | 110,607 -114,393 | -51% | -$8.19M |
|